JP2008512988A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008512988A5 JP2008512988A5 JP2007524978A JP2007524978A JP2008512988A5 JP 2008512988 A5 JP2008512988 A5 JP 2008512988A5 JP 2007524978 A JP2007524978 A JP 2007524978A JP 2007524978 A JP2007524978 A JP 2007524978A JP 2008512988 A5 JP2008512988 A5 JP 2008512988A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- rage
- immunoglobulin
- fusion protein
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108020001507 fusion proteins Proteins 0.000 claims 32
- 102000037865 fusion proteins Human genes 0.000 claims 32
- 108060003951 Immunoglobulin Proteins 0.000 claims 29
- 102000018358 immunoglobulin Human genes 0.000 claims 29
- 108090000765 processed proteins & peptides Proteins 0.000 claims 17
- 229920001184 polypeptide Polymers 0.000 claims 16
- 102000004196 processed proteins & peptides Human genes 0.000 claims 16
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 150000007523 nucleic acids Chemical group 0.000 claims 8
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims 6
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 206010012601 diabetes mellitus Diseases 0.000 claims 4
- 239000013604 expression vector Substances 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 102000002110 C2 domains Human genes 0.000 claims 1
- 108050009459 C2 domains Proteins 0.000 claims 1
- 241000699802 Cricetulus griseus Species 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 208000008960 Diabetic foot Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 102000006395 Globulins Human genes 0.000 claims 1
- 108010044091 Globulins Proteins 0.000 claims 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 108020004511 Recombinant DNA Proteins 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 206010049771 Shock haemorrhagic Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 230000005784 autoimmunity Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 230000007954 hypoxia Effects 0.000 claims 1
- 238000003119 immunoblot Methods 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 239000008176 lyophilized powder Substances 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 210000000287 oocyte Anatomy 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US59855504P | 2004-08-03 | 2004-08-03 | |
| US60/598,555 | 2004-08-03 | ||
| PCT/US2005/027705 WO2006017647A1 (en) | 2004-08-03 | 2005-08-03 | Rage fusion proteins and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008512988A JP2008512988A (ja) | 2008-05-01 |
| JP2008512988A5 true JP2008512988A5 (OSRAM) | 2009-06-04 |
| JP5188804B2 JP5188804B2 (ja) | 2013-04-24 |
Family
ID=35149359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007524978A Expired - Fee Related JP5188804B2 (ja) | 2004-08-03 | 2005-08-03 | Ｒａｇｅ融合タンパク質及びその使用方法 |
Country Status (23)
| Country | Link |
|---|---|
| US (5) | US7901688B2 (OSRAM) |
| EP (1) | EP1781700B1 (OSRAM) |
| JP (1) | JP5188804B2 (OSRAM) |
| KR (1) | KR101323411B1 (OSRAM) |
| CN (1) | CN1993378A (OSRAM) |
| AP (1) | AP2007003869A0 (OSRAM) |
| AU (1) | AU2005271452B2 (OSRAM) |
| BR (1) | BRPI0514052A (OSRAM) |
| CA (1) | CA2570324C (OSRAM) |
| CR (1) | CR20110556A (OSRAM) |
| EA (1) | EA012082B1 (OSRAM) |
| EC (1) | ECSP077221A (OSRAM) |
| ES (1) | ES2473587T3 (OSRAM) |
| GE (1) | GEP20105110B (OSRAM) |
| IL (1) | IL180554A (OSRAM) |
| MA (1) | MA29067B1 (OSRAM) |
| MX (1) | MX2007001559A (OSRAM) |
| NO (1) | NO20065949L (OSRAM) |
| NZ (1) | NZ552128A (OSRAM) |
| TN (1) | TNSN07037A1 (OSRAM) |
| UA (1) | UA93356C2 (OSRAM) |
| WO (1) | WO2006017647A1 (OSRAM) |
| ZA (2) | ZA200700643B (OSRAM) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6465422B1 (en) * | 1998-04-17 | 2002-10-15 | The Trustees Of Columbia University In The City Of New York | Method for inhibiting tumor invasion or spreading in a subject |
| US6303321B1 (en) | 1999-02-11 | 2001-10-16 | North Shore-Long Island Jewish Research Institute | Methods for diagnosing sepsis |
| US7304034B2 (en) | 2001-05-15 | 2007-12-04 | The Feinstein Institute For Medical Research | Use of HMGB fragments as anti-inflammatory agents |
| US7696169B2 (en) * | 2003-06-06 | 2010-04-13 | The Feinstein Institute For Medical Research | Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents |
| EP1668035A2 (en) * | 2003-09-11 | 2006-06-14 | Critical Therapeutics, Inc. | Monoclonal antibodies against hmgb1 |
| AP2007003893A0 (en) * | 2004-08-03 | 2007-02-28 | Transtech Pharma Inc | Rage fusion proteins and methods of use |
| CN1993378A (zh) * | 2004-08-03 | 2007-07-04 | 转化技术制药公司 | Rage融合蛋白及使用方法 |
| WO2006119510A2 (en) * | 2005-05-04 | 2006-11-09 | Receptor Biologix, Inc. | Isoforms of receptor for advanced glycation end products (rage) and methods of identifying and using same |
| CA2631212A1 (en) * | 2005-11-28 | 2007-07-05 | Medimmune, Llc | Antagonists of hmgb1 and/or rage and methods of use thereof |
| WO2007073272A1 (en) * | 2005-12-23 | 2007-06-28 | Gcoder Systems Ab | Positioning pattern |
| CN101410411A (zh) * | 2006-02-09 | 2009-04-15 | 转化技术制药公司 | Rage融合蛋白及使用方法 |
| BRPI0711193A2 (pt) * | 2006-05-05 | 2013-06-18 | Transtech Pharma Inc | proteÍnas de fusço rage, formulaÇÕes e mÉtodos de uso dos mesmos |
| EP2423219B1 (en) | 2007-01-30 | 2015-04-29 | Epivax, Inc. | Regulatory T cell epitopes, compositions and uses thereof |
| US20080199467A1 (en) * | 2007-02-15 | 2008-08-21 | Mjalli Adnan M M | Immunoglobulin fusion proteins and methods of making |
| WO2008153957A1 (en) * | 2007-06-07 | 2008-12-18 | The Trustees Of Columbia University In The City Of New York | Uses of rage antagonists for treating obesity and related diseases |
| EP2158210B1 (en) * | 2007-06-14 | 2015-12-09 | Galactica Pharmaceuticals, Inc. | Rage fusion proteins |
| JP5620106B2 (ja) * | 2007-10-24 | 2014-11-05 | 株式会社糖鎖工学研究所 | 増強されたエフェクター機能を有するポリペプチド |
| NL2001551C2 (nl) * | 2008-05-06 | 2009-05-07 | Transtech Pharma | Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan. |
| NL2001557C2 (nl) * | 2008-05-06 | 2009-05-07 | Transtech Pharma | Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan. |
| NL2001558C2 (nl) * | 2008-05-06 | 2009-05-07 | Transtech Pharma | Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan. |
| NL2001552C2 (nl) * | 2008-05-06 | 2009-05-07 | Transtech Pharma | Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan. |
| NL2001553C2 (nl) * | 2008-05-06 | 2009-05-07 | Transtech Pharma | Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan. |
| NL2001556C2 (nl) * | 2008-05-06 | 2009-05-07 | Transtech Pharma | Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan. |
| NL2001555C2 (nl) * | 2008-05-06 | 2009-05-07 | Transtech Pharma | Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan. |
| NL2001554C2 (nl) * | 2008-05-06 | 2009-05-07 | Transtech Pharma | Rage-fusie-eiwitten, preparaten en werkwijzen voor het gebruik ervan. |
| HUE031902T2 (en) | 2008-05-23 | 2017-08-28 | Siwa Corp | Procedures and Preparations to Promote Regeneration |
| CN102803292A (zh) | 2009-04-20 | 2012-11-28 | 辉瑞公司 | 蛋白质糖基化的控制及其相关组合物和方法 |
| WO2011100508A2 (en) * | 2010-02-12 | 2011-08-18 | Arizona Board Of Regents For And On Behalf Of Arizona State University | Methods and compositions related to glycoprotein-immunoglobulin fusions |
| WO2011102845A1 (en) * | 2010-02-18 | 2011-08-25 | Transtech Pharma, Inc. | Rage fusion protein compositions and methods of use |
| US9649376B2 (en) | 2010-09-27 | 2017-05-16 | Siwa Corporation | Selective removal of age-modified cells for treatment of atherosclerosis |
| US8721571B2 (en) | 2010-11-22 | 2014-05-13 | Siwa Corporation | Selective removal of cells having accumulated agents |
| SG10201601621PA (en) | 2011-06-28 | 2016-04-28 | Inhibrx Llc | Serpin fusion polypeptides and methods of use thereof |
| US10400029B2 (en) | 2011-06-28 | 2019-09-03 | Inhibrx, Lp | Serpin fusion polypeptides and methods of use thereof |
| CN103946388A (zh) * | 2011-06-28 | 2014-07-23 | 英伊布里克斯有限责任公司 | Wap结构域融合多肽及其使用方法 |
| CA2880929A1 (en) * | 2012-09-07 | 2014-03-13 | Sanofi | Fusion proteins for treating a metabolic syndrome |
| WO2015023165A1 (ko) * | 2013-08-16 | 2015-02-19 | 가톨릭대학교 산학협력단 | 염증조절복합체 및 ｓｔａｔ３ 신호분자 차단을 통한 면역조절능 최적화된 안정화 중간엽줄기세포 |
| CA2961603C (en) * | 2014-09-19 | 2021-07-13 | Siwa Corporation | Anti-age antibodies for treating inflammation and auto-immune disorders |
| US9993535B2 (en) | 2014-12-18 | 2018-06-12 | Siwa Corporation | Method and composition for treating sarcopenia |
| US10358502B2 (en) | 2014-12-18 | 2019-07-23 | Siwa Corporation | Product and method for treating sarcopenia |
| KR102786111B1 (ko) | 2016-02-19 | 2025-03-26 | 시와 코퍼레이션 | 고급 당화 최종 산물(age)에 대한 항체를 사용하여 암을 치료하고, 전이성 암 세포를 사멸시키고, 암 전이를 예방하기 위한 방법 및 조성물 |
| AU2017250301A1 (en) | 2016-04-15 | 2018-11-15 | Siwa Corporation | Anti-age antibodies for treating neurodegenerative disorders |
| WO2017211321A1 (zh) * | 2016-06-08 | 2017-12-14 | 上海交通大学医学院 | 增强激动型抗体活性的抗体重链恒定区序列 |
| WO2017222535A1 (en) | 2016-06-23 | 2017-12-28 | Siwa Corporation | Vaccines for use in treating various diseases and disorders |
| US10995151B1 (en) | 2017-01-06 | 2021-05-04 | Siwa Corporation | Methods and compositions for treating disease-related cachexia |
| US10858449B1 (en) | 2017-01-06 | 2020-12-08 | Siwa Corporation | Methods and compositions for treating osteoarthritis |
| US10961321B1 (en) | 2017-01-06 | 2021-03-30 | Siwa Corporation | Methods and compositions for treating pain associated with inflammation |
| US10925937B1 (en) | 2017-01-06 | 2021-02-23 | Siwa Corporation | Vaccines for use in treating juvenile disorders associated with inflammation |
| CN110506054A (zh) * | 2017-02-17 | 2019-11-26 | 戴纳立制药公司 | 经工程改造的多肽 |
| US10143187B2 (en) | 2017-02-17 | 2018-12-04 | Denali Therapeutics Inc. | Transferrin receptor transgenic models |
| US10457717B2 (en) | 2017-02-17 | 2019-10-29 | Denali Therapeutics Inc. | Engineered polypeptides |
| EP3609923A1 (en) | 2017-04-13 | 2020-02-19 | Siwa Corporation | Humanized monoclonal advanced glycation end-product antibody |
| EP3658172A4 (en) | 2017-07-25 | 2021-05-05 | TrueBinding, Inc. | TREATING CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND HIS LIGAND |
| AU2018322482B2 (en) | 2017-08-22 | 2024-04-04 | Monash University | Screening assays, modulators and modulation of activation of receptor for advanced glycation end-products (RAGE) |
| US11518801B1 (en) | 2017-12-22 | 2022-12-06 | Siwa Corporation | Methods and compositions for treating diabetes and diabetic complications |
| WO2020056379A1 (en) | 2018-09-14 | 2020-03-19 | BioAge Labs, Inc. | Rage fusion proteins with improved stability and ligand binding affinity and uses thereof |
| CN113711036B (zh) | 2019-01-30 | 2025-03-18 | 真和制药有限公司 | 抗gal3抗体及其用途 |
| CN116157151A (zh) | 2020-05-26 | 2023-05-23 | 真和制药有限公司 | 通过阻断半乳凝素-3治疗炎性疾病的方法 |
Family Cites Families (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4867973A (en) | 1984-08-31 | 1989-09-19 | Cytogen Corporation | Antibody-therapeutic agent conjugates |
| US5567584A (en) | 1988-01-22 | 1996-10-22 | Zymogenetics, Inc. | Methods of using biologically active dimerized polypeptide fusions to detect PDGF |
| US6018026A (en) * | 1988-01-22 | 2000-01-25 | Zymogenetics, Inc. | Biologically active dimerized and multimerized polypeptide fusions |
| NZ235148A (en) * | 1989-09-05 | 1991-12-23 | Immunex Corp | Tumour necrosis factor receptor protein and dna sequences |
| MX9204374A (es) * | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| SE9201073D0 (sv) | 1992-04-03 | 1992-04-03 | Kabi Pharmacia Ab | Protein formulation |
| ATE240394T1 (de) | 1992-10-23 | 2003-05-15 | Immunex Corp | Methoden zur herstellung löslicher, oligomerer proteine |
| US5656261A (en) | 1995-01-18 | 1997-08-12 | The Picower Institute For Medical Research | Preventing and reversing advanced glycosylation endproducts |
| CA2210684C (en) | 1995-01-18 | 2008-01-15 | Alteon Inc. | Use of thiazolium compounds for preventing and reversing the formation of advanced glycosylation endproducts |
| FI119756B (fi) * | 1995-01-18 | 2009-03-13 | Alteon Inc | Tiatsoliumyhdisteiden käyttö pitkälle edenneen glykosylaation lopputuotteiden muodostumisen estossa ja suunnan muutoksessa |
| EP0827511A1 (en) | 1995-04-05 | 1998-03-11 | The Picower Institute For Medical Research | Agents for binding to advanced glycosylation endproducts, and methods of their use |
| US5747035A (en) | 1995-04-14 | 1998-05-05 | Genentech, Inc. | Polypeptides with increased half-life for use in treating disorders involving the LFA-1 receptor |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| AU1832797A (en) | 1996-01-26 | 1997-08-20 | Trustees Of Columbia University In The City Of New York, The | A polypeptide from lung extract which binds amyloid-beta peptide |
| AU2696097A (en) | 1996-04-16 | 1997-11-07 | Schering Aktiengesellschaft | Advanced glycosylation end-product receptor peptides and uses therefor |
| US5864018A (en) | 1996-04-16 | 1999-01-26 | Schering Aktiengesellschaft | Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor |
| US7258857B2 (en) * | 1996-11-22 | 2007-08-21 | The Trustees Of Columbia University In The City Of New York | Rage-related methods for treating inflammation |
| US7081241B1 (en) | 1998-10-06 | 2006-07-25 | The Trustees Of Columbia University In The City Of New York | Extracellular rage binding protein (EN-RAGE) and uses thereof |
| US6555651B2 (en) | 1997-10-09 | 2003-04-29 | The Trustees Of Columbia University In The City Of New York | Ligand binding site of rage and uses thereof |
| US6790443B2 (en) * | 1996-11-22 | 2004-09-14 | The Trustees Of Columbia University In The City Of New York | Method for treating symptoms of diabetes |
| AU748768B2 (en) | 1997-03-11 | 2002-06-13 | General Hospital Corporation, The | Identification of agents for use in the treatment of Alzheimer's disease |
| US6165476A (en) | 1997-07-10 | 2000-12-26 | Beth Israel Deaconess Medical Center | Fusion proteins with an immunoglobulin hinge region linker |
| US7101838B2 (en) | 1997-08-05 | 2006-09-05 | The Trustees Of Columbia University In The City Of New York | Method to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts |
| ZA988461B (en) | 1997-09-18 | 1999-03-30 | Idec Pharma Corp | Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis |
| US6380165B1 (en) | 1997-09-19 | 2002-04-30 | The Picower Institute For Medical Research | Immunological advanced glycation endproduct crosslink |
| US6761888B1 (en) * | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
| US6323218B1 (en) | 1998-03-11 | 2001-11-27 | The General Hospital Corporation | Agents for use in the treatment of Alzheimer's disease |
| US6465422B1 (en) | 1998-04-17 | 2002-10-15 | The Trustees Of Columbia University In The City Of New York | Method for inhibiting tumor invasion or spreading in a subject |
| US6706683B1 (en) | 1998-09-29 | 2004-03-16 | Asahi Kasei Pharma Corporation | Method for controlling the release of granules |
| US6753150B2 (en) * | 1998-10-05 | 2004-06-22 | The Trustees Of Columbia University In The City Of New York | Method for determining whether a compound is capable of inhibiting the interaction of a peptide with rage |
| ES2299267T3 (es) * | 1998-10-06 | 2008-05-16 | The Trustees Of Columbia University In The City Of New York | Nueva proteina extracelular ligante de rage (en-rage) y sus usos. |
| US6197294B1 (en) * | 1998-10-26 | 2001-03-06 | Neurotech S.A. | Cell surface molecule-induced macrophage activation |
| US6605642B2 (en) | 1999-04-05 | 2003-08-12 | City Of Hope | Inhibitors of formation of advanced glycation endproducts (AGES) |
| US6787566B2 (en) | 1999-04-05 | 2004-09-07 | City Of Hope | Breakers of advanced glycation endproducts |
| US6589944B1 (en) | 1999-04-05 | 2003-07-08 | City Of Hope | Breakers of advanced glycation endproducts |
| US6939545B2 (en) * | 1999-04-28 | 2005-09-06 | Genetics Institute, Llc | Composition and method for treating inflammatory disorders |
| US6835200B2 (en) | 1999-06-22 | 2004-12-28 | Ndo Surgical. Inc. | Method and devices for tissue reconfiguration |
| FR2797402B1 (fr) | 1999-07-15 | 2004-03-12 | Biomerieux Stelhys | Utilisation d'un polypeptide pour detecter, prevenir ou traiter un etat pathologique associe a une maladie degenerative, neurologique ou autoimmune |
| EP1307219A4 (en) * | 1999-08-13 | 2005-04-06 | Univ Columbia | METHODS OF INHIBITING BETA FIBRILLE BINDING BETA TO RAGE RECEPTOR, AND CONSEQUENCES THEREOF |
| EP1219639A4 (en) | 1999-09-08 | 2009-03-25 | Toray Industries | CIPO - Patent |
| US20050170382A1 (en) | 1999-10-06 | 2005-08-04 | The Trustees Of Columbia University In The City Of New York. | RAGE-related compositions |
| AU784861B2 (en) | 1999-10-21 | 2006-07-06 | Case Western Reserve University | Gene expression profiling of inflammatory bowel disease |
| CA2382165A1 (en) | 1999-12-08 | 2001-06-14 | Genset S.A. | Full-length human cdnas encoding potentially secreted proteins |
| US6727353B2 (en) * | 2000-04-14 | 2004-04-27 | Icagen, Inc. | Nucleic acid encoding Kv10.1, a voltage-gated potassium channel from human brain |
| EP1272843B1 (en) * | 2000-04-14 | 2007-06-20 | Niadyne Corporation | Method for identifying regulators of protein-age formation |
| WO2001079849A2 (en) | 2000-04-17 | 2001-10-25 | Trans Tech Pharma | Protein expression system arrays and use in biological screening |
| JP2005520479A (ja) | 2000-05-09 | 2005-07-14 | ジェネティクス インスティテュート，エルエルシー | 乾癬の確認、評価、予防および治療のための組成物、キットおよび方法 |
| US6613801B2 (en) | 2000-05-30 | 2003-09-02 | Transtech Pharma, Inc. | Method for the synthesis of compounds of formula I and their uses thereof |
| US6908741B1 (en) | 2000-05-30 | 2005-06-21 | Transtech Pharma, Inc. | Methods to identify compounds that modulate RAGE |
| US6583015B2 (en) * | 2000-08-07 | 2003-06-24 | Amberwave Systems Corporation | Gate technology for strained surface channel and strained buried channel MOSFET devices |
| US6825164B1 (en) * | 2000-08-14 | 2004-11-30 | The Trustees Of Columbia University In The City Of New York | Method to increase cerebral blood flow in amyloid angiopathy |
| US6563015B1 (en) * | 2000-08-14 | 2003-05-13 | The Trustees Of Columbia University In The City Of New York | Transgenic mice over-expressing receptor for advanced glycation endproduct (RAGE) and mutant APP in brain and uses thereof |
| EA200300442A1 (ru) * | 2000-10-02 | 2003-10-30 | Редди Ю Эс Терапьютикс, Инк. | Способы и композиции для лечения воспалительных заболеваний |
| AU2002213192A1 (en) | 2000-10-13 | 2002-04-22 | The Trustees Of Columbia University In The City Of New York | A method for inhibiting new tissue growth in blood vessels in a patient subjected to blood vessel injury |
| US20050244849A1 (en) * | 2000-12-15 | 2005-11-03 | Genetics Institute, Llc | Screening assays for rheumatoid arthritis |
| IL156651A0 (en) | 2000-12-29 | 2004-01-04 | Reddy Us Therapeutics Inc | Detection of compounds that modulate inflammatory responses |
| US6946277B2 (en) | 2001-01-31 | 2005-09-20 | Council Of Scientific And Industrial Research | Method for enhancing cellobiase activity of termitomyces clypeatus using a glycosylation inhibitor |
| PL362324A1 (en) | 2001-02-19 | 2004-10-18 | Merck Patent Gmbh | Artificial fusion proteins with reduced immunogenicity |
| DE10109466B4 (de) | 2001-02-28 | 2008-01-10 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Verfahren und Mittel zur Modifikation humaner Angiogenese |
| JP3837494B2 (ja) | 2001-03-19 | 2006-10-25 | 国立大学法人金沢大学 | 可溶型ｒａｇｅタンパク質 |
| ATE297944T1 (de) * | 2001-03-22 | 2005-07-15 | Vlaams Interuniv Inst Biotech | Verfahren und vorrichtung zur gel-freien qualitativen proteomanalyse und deren verwendungen |
| US7304034B2 (en) * | 2001-05-15 | 2007-12-04 | The Feinstein Institute For Medical Research | Use of HMGB fragments as anti-inflammatory agents |
| US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
| AU2003248921A1 (en) | 2002-07-09 | 2004-01-23 | Point Therapeutics, Inc. | Boroproline compound combination therapy |
| WO2004016229A2 (en) * | 2002-08-16 | 2004-02-26 | Wyeth | Compositions and methods for treating rage-associated disorders |
| US7261893B2 (en) | 2002-10-22 | 2007-08-28 | Wyeth | Neutralizing antibodies against GDF-8 and uses therefor |
| EP1578797A1 (en) | 2002-12-13 | 2005-09-28 | Licentia Ltd. | The transmembrane protein amigo and uses thereof |
| NZ542586A (en) | 2003-04-09 | 2009-11-27 | Biogenerix Ag | Method of forming a covalent conjugate between a G-CSF peptide and PEG |
| WO2004100890A2 (en) * | 2003-05-09 | 2004-11-25 | The Trustees Of Columbia University In The City Of New York | Rage g82s-related methods and compositions for treating inflammatory disorders |
| CN1805743A (zh) * | 2003-05-20 | 2006-07-19 | 特兰斯泰克制药公司 | 用作逆转淀粉样变性及其他与之相关疾病的rage拮抗剂 |
| WO2005021710A2 (en) | 2003-06-02 | 2005-03-10 | University Of Miami | Chimeric molecules and methods of use |
| WO2005019429A2 (en) | 2003-08-22 | 2005-03-03 | Potentia Pharmaceuticals, Inc. | Compositions and methods for enhancing phagocytosis or phagocyte activity |
| WO2005023191A2 (en) | 2003-09-05 | 2005-03-17 | The Trustees Of Columbia University In The City Of New York | Rage-related methods and compositions for treating glomerular injury |
| US20070167360A1 (en) * | 2003-10-31 | 2007-07-19 | Yan Shi D | Methods for treating multiple sclerosis |
| US8003613B2 (en) | 2003-11-17 | 2011-08-23 | University Of Florida Research Foundation, Inc. | Methods and compositions for inducing apoptosis |
| WO2005051995A2 (en) | 2003-11-19 | 2005-06-09 | Curagen Corporation | Novel advanced glycosylation end product-specific receptor-like protein and nucleic acids encoding same |
| GB0330079D0 (en) | 2003-12-20 | 2004-02-04 | Bioinvent Int Ab | Vaccine |
| CN100342017C (zh) | 2004-05-10 | 2007-10-10 | 中国医学科学院肿瘤医院肿瘤研究所 | 基因重组趋化抗原疫苗 |
| AU2005259381A1 (en) | 2004-07-02 | 2006-01-12 | Creabilis Therapeutics S.P.A. | Nucleic acids for the treatment of HMGB1-related pathologies |
| US20060012414A1 (en) * | 2004-07-15 | 2006-01-19 | Texas Instruments Incorporated | Circuit and method for generating a polyphase clock signal and system incorporating the same |
| EP1814576A2 (en) | 2004-07-20 | 2007-08-08 | Critical Therapeutics, Inc. | Combination therapies of hmgb and complement inhibitors against inflammation |
| EP1771565B1 (en) | 2004-07-20 | 2012-09-05 | The Feinstein Institute for Medical Research | Rage protein derivatives |
| AP2007003893A0 (en) | 2004-08-03 | 2007-02-28 | Transtech Pharma Inc | Rage fusion proteins and methods of use |
| CN1993378A (zh) * | 2004-08-03 | 2007-07-04 | 转化技术制药公司 | Rage融合蛋白及使用方法 |
| EP1799700A4 (en) * | 2004-09-27 | 2009-02-11 | Centocor Inc | SRAGE MIMETIC BODIES, COMPOSITIONS, PROCESSES AND USES |
| WO2006119510A2 (en) | 2005-05-04 | 2006-11-09 | Receptor Biologix, Inc. | Isoforms of receptor for advanced glycation end products (rage) and methods of identifying and using same |
| US20080207499A1 (en) * | 2005-06-29 | 2008-08-28 | Gaetano Barile | Rage-related methods for treating and preventing diabetic retinopathy |
| CN101410411A (zh) * | 2006-02-09 | 2009-04-15 | 转化技术制药公司 | Rage融合蛋白及使用方法 |
| BRPI0711193A2 (pt) | 2006-05-05 | 2013-06-18 | Transtech Pharma Inc | proteÍnas de fusço rage, formulaÇÕes e mÉtodos de uso dos mesmos |
| US8192951B2 (en) | 2006-11-03 | 2012-06-05 | Wyeth Llc | Glycolysis-inhibiting substances in cell culture |
| US20080199467A1 (en) * | 2007-02-15 | 2008-08-21 | Mjalli Adnan M M | Immunoglobulin fusion proteins and methods of making |
| EP2158210B1 (en) | 2007-06-14 | 2015-12-09 | Galactica Pharmaceuticals, Inc. | Rage fusion proteins |
-
2005
- 2005-08-03 CN CNA2005800259477A patent/CN1993378A/zh active Pending
- 2005-08-03 NZ NZ552128A patent/NZ552128A/en not_active IP Right Cessation
- 2005-08-03 AU AU2005271452A patent/AU2005271452B2/en not_active Ceased
- 2005-08-03 GE GEAP20059904A patent/GEP20105110B/en unknown
- 2005-08-03 ES ES05778764.0T patent/ES2473587T3/es not_active Expired - Lifetime
- 2005-08-03 US US11/197,038 patent/US7901688B2/en not_active Expired - Fee Related
- 2005-08-03 CA CA2570324A patent/CA2570324C/en not_active Expired - Fee Related
- 2005-08-03 EA EA200700404A patent/EA012082B1/ru not_active IP Right Cessation
- 2005-08-03 EP EP05778764.0A patent/EP1781700B1/en not_active Expired - Lifetime
- 2005-08-03 WO PCT/US2005/027705 patent/WO2006017647A1/en not_active Ceased
- 2005-08-03 US US11/629,437 patent/US7981423B2/en not_active Expired - Fee Related
- 2005-08-03 AP AP2007003869A patent/AP2007003869A0/xx unknown
- 2005-08-03 BR BRPI0514052-8A patent/BRPI0514052A/pt not_active IP Right Cessation
- 2005-08-03 MX MX2007001559A patent/MX2007001559A/es active IP Right Grant
- 2005-08-03 UA UAA200702273A patent/UA93356C2/ru unknown
- 2005-08-03 JP JP2007524978A patent/JP5188804B2/ja not_active Expired - Fee Related
- 2005-08-03 KR KR1020077005152A patent/KR101323411B1/ko not_active Expired - Fee Related
-
2006
- 2006-12-21 NO NO20065949A patent/NO20065949L/no not_active Application Discontinuation
-
2007
- 2007-01-04 IL IL180554A patent/IL180554A/en not_active IP Right Cessation
- 2007-01-23 ZA ZA200700643A patent/ZA200700643B/xx unknown
- 2007-02-02 TN TNP2007000037A patent/TNSN07037A1/fr unknown
- 2007-02-02 EC EC2007007221A patent/ECSP077221A/es unknown
- 2007-02-02 MA MA29650A patent/MA29067B1/fr unknown
-
2009
- 2009-09-16 ZA ZA200906459A patent/ZA200906459B/xx unknown
-
2011
- 2011-01-03 US US12/983,604 patent/US8877192B2/en not_active Expired - Fee Related
- 2011-01-07 US US12/986,602 patent/US20110124102A1/en not_active Abandoned
- 2011-02-17 US US13/029,622 patent/US20110244516A1/en not_active Abandoned
- 2011-10-20 CR CR20110556A patent/CR20110556A/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2006304846B2 (en) | Methods for generating monovalent IgG | |
| TWI608015B (zh) | 具有組織標的功能的抗發炎分子 | |
| JP2008508882A5 (OSRAM) | ||
| RU2427589C2 (ru) | Антитела против интерлейкина-13 человека и их применение | |
| JP2009523459A5 (OSRAM) | ||
| JP2020500885A5 (OSRAM) | ||
| JP2021508449A5 (OSRAM) | ||
| JP2011506476A5 (OSRAM) | ||
| JP2008515446A5 (OSRAM) | ||
| JP2010532764A5 (OSRAM) | ||
| TW201706312A (zh) | 用以治療疾病的分子構建體 | |
| TW201336865A (zh) | 免疫球蛋白Ｆｃ變體 | |
| RU2007119989A (ru) | Композиции, слитые конструкции и конъюгаты plad домена | |
| CN109796534B (zh) | 抗il-17抗体/tnfr ecd融合蛋白及其用途 | |
| TWI691512B (zh) | Ｆｃ融合高親和性ＩｇＥ受體α鏈 | |
| EP4303231A1 (en) | Bispecific antibody | |
| JP2018503355A5 (OSRAM) | ||
| CN103897057B (zh) | 多价抗体片段与其三聚复合物 | |
| JP2005522192A5 (OSRAM) | ||
| JP2025517120A5 (OSRAM) | ||
| CA3236737A1 (en) | Novel proteins | |
| CN107074976B (zh) | 同时阻断b7/cd28和il6/il6r/gp130信号通路的重组融合蛋白 | |
| US7557084B2 (en) | IL-18 specific polypeptides and therapeutic uses thereof | |
| Herring et al. | AlbudAb™ Technology Platform–Versatile Albumin Binding Domains for the Development of Therapeutics with Tunable Half‐Lives | |
| US20240141026A1 (en) | Use of a periostin antibody for treating inflammation, fibrosis and lung diseases |